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INTRODUCTION
Crohn's disease is an idiopathic, chronic, in¯ammatory
disease of the gastrointestinal tract that primarily affects
the small intestine and colon. Crohn's disease is
associated with signi®cant morbidity, the need for
treatment with sulfasalazine, mesalamine, corticoster-
oids and other immunomodulating agents, surgical
resection of the intestine and a slightly increased
mortality.1 Knowledge of the natural history of Crohn's
disease (e.g. the likelihood of surgical intervention or
the likelihood of experiencing a ¯are of Crohn's disease
in a given year) guides physicians when counselling
Crohn's disease patients and offering advice regarding
treatment options. More importantly, Crohn's disease is
an idiopathic disorder, which may be caused by a
combination of environmental and genetic factors.
Better understanding of the epidemiology of Crohn's
disease (e.g. differences in prevalence of Crohn's disease
based on gender or geographical region) may identify
areas for further research.
SUMMARY
Aim: To quantify, through systematic review, the
epidemiology and natural history of Crohn's disease in
North America.
Methods: The selected articles contained: (i) population-
based samples of patients followed from the time of
diagnosis; and (ii) objective diagnostic criteria for
disease. Studies on the natural history of Crohn's
disease also contained suf®cient follow-up.
Data collection and analysis: For prevalence studies, data
on the incidence, prevalence, gender and age at
diagnosis were extracted. For natural history studies,
data on the disease activity, use of medications and
surgery were extracted.
Main results: The prevalence of Crohn's disease in
North America ranges from 26.0 to 198.5 cases per
100 000 persons. The incidence rates range from 3.1
to 14.6 cases per 100 000 person-years. Most
patients have a chronic intermittent disease course,
while 13% have an unremitting disease course and
10% have a prolonged remission. Less than half
require corticosteroids at any point. During any given
year, approximately 10% are treated with corticoster-
oids and 30% are treated with 5-aminosalicylates. Up
to 57% of patients require at least one surgical
resection.
Conclusions: Between 400 000 and 600 000 patients
in North America have Crohn's disease, and the natural
history is marked by frequent exacerbations requiring
treatment with corticosteroids, 5-aminosalicylate prod-
ucts and surgery.
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Multiple studies have reported the incidence, preval-
ence, gender distribution and age of onset of Crohn's
disease in well-de®ned, population-based cohorts of
patients in North America and Western Europe.2
However, these trials have reported a wide variation
in the prevalence and incidence of Crohn's disease.
Some of these differences between studies may be due
to different study methodologies, while some differences
in trial results may be due to true differences in the
genetic or environmental factors present in certain
populations. Multiple studies have also reported wide
variations in the natural history of Crohn's disease.
Many of these studies utilized referral centre popula-
tions, which may create a `referral centre' bias (i.e.
patients referred to quaternary medical centres may
have the most severe disease activity levels and be
more likely to undergo surgery and use multiple
medications). Therefore, studies of the natural history
of Crohn's disease should be performed in well-de®ned,
population-based patient cohorts.3±9 The use of sys-
tematic reviews may facilitate the identi®cation of
appropriately designed studies and a comprehensive
evaluation of divergent results, while delineating topics
that require further research.
Systematic reviews utilize comprehensive literature
searches, with pre-speci®ed inclusion criteria for the
selection of studies, and duplicate extraction of data by
independent investigators. These techniques minimize
bias in the identi®cation of appropriately designed
studies and in the extraction of study data. This
systematic review quanti®es the prevalence and inci-
dence of Crohn's disease in North America and
describes the gender distribution and the age at
diagnosis among Crohn's disease patients. In order
to better de®ne the natural history of Crohn's disease,
this systematic review also addresses: (i) the percent-
age of Crohn's disease patients with inactive or
quiescent, mildly active, moderately active or severely
active Crohn's disease in a given year; (ii) the
percentage of Crohn's disease patients experiencing a
¯are of active Crohn's disease in a given year; (iii) the
percentage of Crohn's disease patients treated with
conventional steroids in a given year; (iv) the
percentage of Crohn's disease patients treated with
5-aminosalicylate products in a given year; and (v)
the percentage of Crohn's disease patients treated with
surgery.
METHODS
Search strategy for the identi®cation of studies
A search of the on-line bibliographic database MED-
LINE was carried out to identify potentially relevant
English language articles published between 1966 and
September 2000. The Medical Subject Heading (MeSH)
terms `Crohn's disease [epidemiology]' or `in¯amma-
tory bowel disease [epidemiology]', and `Crohn's dis-
ease' or `in¯ammatory bowel disease' and `prognosis'
were used to perform keyword searches of the
database. However, recently published literature is
not always included in the MEDLINE database. There-
fore, the on-line bibliographic database Current Con-
tents/Science Edition was also searched for articles
published between 1996 and September 2000 using
the keywords `Crohn's disease' OR `Crohn disease'
AND `incidence' or `prevalence'. Manual searches of
the reference lists from the potentially relevant papers
were performed in order to identify additional studies
that may have been missed using the computer-
assisted search strategy.
Study selection criteria
Laupacis et al.10 de®ned criteria for properly designed
studies of natural history and prevalence, including the
use of: (a) samples of patients followed from the time of
initial diagnosis (i.e. inception cohort); (b) appropriate
and objective diagnostic criteria for disease; and (c)
suf®ciently long and complete follow-up using objective
de®nitions of disease activity.
For studies on the prevalence and incidence of Crohn's
disease in North America, study selection criteria were:
(i) samples of North American patients followed from
the time of initial diagnosis (i.e. inception cohort);
(ii) appropriate and objective diagnostic criteria for
disease; (iii) quanti®cation of the prevalence, incidence,
gender distribution and age at diagnosis; and (iv)
published in full manuscript form.
For studies about the natural history of Crohn's
disease, study selection criteria were: (i) population-
based samples of patients followed from the time of
initial diagnosis (i.e. inception cohort); (ii) appropriate
and objective diagnostic criteria for disease; (iii) suf®-
ciently long and complete follow-up using objective
de®nitions of disease activity; (iv) quanti®cation of
disease activity and use of corticosteroids, sulfasal-
azine/mesalamine, other immunomodulators and
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surgery; and (v) published in full manuscript form.
Various criteria for the diagnosis of Crohn's disease and
variable de®nitions of disease activity were considered to
be acceptable. Representative criteria are summarized in
Tables 1 and 2.
Potentially relevant articles were reviewed independ-
ently by two authors (EVL, WJS) to determine if they
met the criteria speci®ed above. Reviewers rated each
article as eligible, ineligible or as having insuf®cient
information to make a judgement about eligibility.
Any disagreement among reviewers was resolved by
consensus.
Data extraction and analysis
Eligible articles were reviewed in a blind fashion by two
different investigators (EVL, WJS) and the results of the
primary research studies were abstracted onto specially
designed data extraction forms. Agreement between
investigators was greater than 95%, and disagreement
in data extraction was resolved by consensus. For
studies on the prevalence of Crohn's disease in North
America, the rates of incidence and prevalence, gender
distribution and mean and median age of onset were
extracted. For studies on the natural history of Crohn's
disease, the disease severity or activity, use of medical
therapy with sulfasalazine/mesalamine or corticoster-
oids and rates of surgical resection for each study were
derived from life tables, survival curves or, where
possible, by calculating life tables from the data
provided.
Data extracted from the original research articles were
converted into individual tables (incidence, prevalence
or gender distribution with 95% con®dence intervals).
Age at diagnosis was also converted into individual
tables (sample size, median, range, mean, standard
deviation). Disease activity and the rates of medical
therapy with sulfasalazine/mesalamine or corticoster-
oids and surgical resection were converted into individ-
ual tables. The tables are presented in a descriptive
form. Due to the signi®cant variability in the methods of
reporting data, no attempt was made to pool the
incidence or prevalence rates, gender distribution data,
age at diagnosis data or data regarding the disease
activity or severity, course or medical and surgical
therapy.
Table 1. Criteria for the diagnosis of Crohn's disease
Olmsted County, MN, criteria (at least two of the following
criteria present)13
History of abdominal pain, weight loss, malaise, rectal bleeding
or diarrhoea
Characteristic endoscopic ®ndings of ulceration, cobblestoning,
®stula or perianal disease
Radiological features of stricture, ®stula or cobblestoning
Macroscopic evidence of typical bowel wall induration,
lymphadenopathy or serosal involvement at laparoscopy
Histopathology consistent with Crohn's disease
Table 2. Criteria for de®nitions of disease activity in Crohn's
disease
Olmsted County, MN, criteria
Disease severity de®ned by the type of therapy and by the patient's
response to therapy8
Most intensive therapy (in descending order of intensity)
1 Surgery
2 Immune modi®er or corticosteroid
3 Sulfasalazine, 5-aminosalicylate, antibiotics or topical
therapy, including topical corticosteroids
4 No medication
Patients were then categorized into one of eight disease severity
states at any given point in time
1 Remission or no medication state: no medication for Crohn's
disease (excluding anti-diarrhoeals)
2 Mild disease: treatment with sulfasalazine, a 5-aminosalicylate
(mesalamine or olsalazine), an antibiotic (metronidazole or
cipro¯oxacin) or topical therapy, including topical
corticosteroids
3 Severe disease, drug-responsive: treatment with oral
corticosteroids or immunosuppressive medications
(6-mercaptopurine, azathioprine, methotrexate or
ciclosporin A) with documented improvement
4 Severe disease, drug-dependent: treatment with oral steroids
or immunosuppressive therapy lasting more than
6 months, with documented improvement
5 Severe disease, drug-refractory: treatment with oral steroids or
immunosuppressive therapy with no documentation of
clinical improvement within 2 months for corticosteroids
or within 6 months for immunosuppressive medication
(patients receiving corticosteroids for more than 6 months
who had evidence of continuing high activity, as de®ned by
stool pattern, abdominal pain, fever or weight loss, were
classi®ed as drug-refractory)
6 Surgery: in-patient surgical procedures for Crohn's disease
(the surgery state included the entire hospital admission and
6 weeks of post-hospitalization convalescence; minor
surgical procedures performed in the out-patient setting
were excluded)
7 Post-surgical remission: no medication or treatment for
Crohn's disease following surgical procedure for Crohn's
disease
8 Death: death from any cause
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RESULTS
Characteristics of selected studies
One thousand, one hundred and thirty-eight references
were reviewed. Fifteen studies of 10 cohorts satis®ed the
inclusion criteria for incidence cohort studies to deter-
mine the prevalence, incidence, gender distribution and
age of onset of Crohn's disease in North America.11±25
In several instances, case ascertainment was hospital-
based.15±17, 22±24 In other studies, case ascertainment
was population-based.11±14, 19, 21, 25 In two studies,
case ascertainment was both hospital- and population-
based.18, 20 All potential diagnoses were con®rmed by
medical record review in 12 studies11±18, 20±25 or by the
use of a validated database.19 Three studies in one
population-based cohort longitudinally satis®ed the
inclusion criteria for incidence cohort studies to deter-
mine the natural history of Crohn's disease.7±9
Prevalence of Crohn's disease in North America
Studies on the prevalence of Crohn's disease in North
America have produced widely disparate estimates,
which may represent the effect of environmental factors
or genetic factors in the development of Crohn's disease.
Four North American cohort studies14, 19±21 reported
adequately on the prevalence of Crohn's disease
(Table 3). The prevalence rates ranged from 26.0 to
198.5 cases per 100 000 persons. Based on an estimate
of 300 million people in North America and rates from
the two most recent studies, there are approximately
400 000±600 000 patients with Crohn's disease in
North America.
Generally, more recent studies demonstrate higher
prevalence rates. This ®nding, in combination with
recently stable incidence rates (see below), suggests that
individuals may be living longer with Crohn's disease.
In Olmsted County, MN, USA, the prevalence was
assessed at three points in time. The prevalence rose
from 91 to 144 cases per 100 000 persons between
1983 and 1991, an increase of 58% over 8 years.14
The two studies with the highest prevalence rates were
performed in the 1990s.14, 19 The study with the lowest
prevalence rate was performed in a staff-model health
maintenance organization in southern California in the
1980s.20 This low prevalence rate may re¯ect either the
relatively large Hispanic population in this cohort or an
effect from the speci®c geographical region.20
Hispanics may have a lower prevalence of Crohn's
disease than Caucasians. The study with the lowest
prevalence of Crohn's disease20 examined a population
that was 31% Hispanic. In this study, the prevalence of
Crohn's disease among Hispanics was one-tenth that of
Caucasians (4.1 vs. 43.6 cases per 100 000 persons).
The other three study populations were predominantly
Caucasian.14, 19, 21 However, this ®nding may also be
related to environmental exposures found in northern
latitudes. The three study populations with the higher
prevalence rates were all located in northern lati-
tudes.14, 19, 21 The two studies with the highest preval-
ence14, 19 were performed within 3 years of each other
in locations only 400 miles apart.
Incidence of Crohn's disease in North America
Studies on the incidence of Crohn's disease in North
America have also produced widely disparate esti-
mates. Incidence rates from the 10 most recent North
American cohort studies are shown in Table 4.
Incidence rates ranged from 3.1 to 14.6 cases per
100 000 person-years. Based on an estimate of 300
million people in North America, approximately 9000±
44 000 people are diagnosed with Crohn's disease
each year.
The analysis of the study results reinforces the
demographic information obtained from the prevalence
Table 3. Prevalence of Crohn's disease in North America
Study (reference) Setting Case ascertainment Source population size Prevalence date Prevalence*
Pinchbeck et al.21 Northern Alberta Population-based 1295000 12/31/81 44.4
Kurata et al.20 Southern California HMO, out-patient 627000 1988 26.0
Loftus et al.14 Olmsted County, MN Population-based 106000 1/1/91 144.1 
Bernstein et al.19 Manitoba Population-based 1140000 12/31/94 198.5 
HMO, health maintenance organization.
* Cases per 100 000 persons (most recent prevalence data for source population shown).
  Rates known to be age- and sex-adjusted.
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data. The incidence of Crohn's disease appears to be
increasing, appears to be more common in northern
latitudes and appears to be more common in Cauca-
sians.14, 17, 19, 21, 25 A series of population-based stud-
ies from Olmsted County, MN, extending from 1935 to
1993, demonstrated that the incidence of Crohn's
disease rapidly increased between the late 1950s and
early 1970s and then stabilized at roughly 7 cases per
100 000 person-years.12±14 The two highest incidence
rates were noted in Canadian locales. However, a
`north±south gradient' of incidence was not universally
observed.18 One of the highest incidence rates noted
was among African±American children in Georgia.25
A series of hospital-based studies from Baltimore noted
the different incidence rates between Caucasians and
non-Caucasians: 3.4±3.5 cases per 100 000 person-
years by 1977±79 in Caucasians vs. 1.3 cases per
100 000 person-years by 1977±79 in non-Caucasian
men.15, 16
Gender distribution and age of onset of Crohn's disease
The gender distribution of Crohn's disease was available
in all 10 cohorts (Table 5), and there appeared to be a
slight female predominance, with the percentage of
females ranging from 48% to 66%. In seven studies, the
female prevalence ranged between 50% and 60%. The
female predominance was over 60% in two stud-
ies,18, 21 both performed 20 years ago. It was under
50% in only one study, performed three decades ago.24
Information on the age at diagnosis of Crohn's disease
was explicitly presented in only two studies.14, 20 The
mean age at diagnosis could be estimated from tables
showing the age distribution in ®ve additional
Table 4. Incidence of Crohn's disease in North America
Study (reference) Setting Case ascertainment Source population size Incidence date Incidence*
Garland et al.24 15 cities, USA Hospital 1070000 1973 4.5 
Calkins et al.16 Baltimore, MD Hospital 2174000 1977±79 3.1 
Nunes and Ahlquist17 Spokane, WA Hospital 171000 1981 8.8
Pinchbeck et al.21 Northern Alberta Population-based 1295000 1981 10 
Hiatt and Kaufman18 Northern California HMO, out-patient 156000 1980±81 7.0
HMO, hospital 1700000 1982 8.2
Stowe et al.22 Monroe County, NY Hospital 700000 1980±89 3.9
Kurata et al.20 Southern California HMO, out-patient 627000 1987±88 3.6
HMO, hospital 1994000 1988 5.4
Loftus et al.14 Olmsted County, MN Population-based 106000 1984±93 6.9 
Bernstein et al.19 Manitoba Population-based 1140000 1989±94 14.6
Ogunbi et al.25 Georgia African±American
children only
748000 1986±95 8.8
HMO, health maintenance organization.
* Cases per 100 000 person-years (most recent incidence data for source population shown).
  Rates known to be age- and sex-adjusted.
Table 5. Sex distribution of Crohn's disease
in North America
Study (reference) Years Type and number of cases Female (%)
Garland et al.24 1973 44 incidence 48
Nunes and Ahlquist17 1971, 1981 41 incidence 60
Calkins et al.16 1977±79 183 incidence 55
Pinchbeck et al.21 1981 1011 prevalence 66
Hiatt and Kaufman18 1980±81 11 incidence 64
Stowe et al.22 1973±86 784 incidence 54
Kurata et al.20 1987±88 169 prevalence 58
Loftus et al.14 1940±93 225 incidence 54
1991 145 prevalence 50
Ogunbi et al.25 1986±95 34 incidence 53
Bernstein et al.19 1994 2268 prevalence 59
1989±94 997 incidence 59
EPIDEMIOLOGY AND NATURAL HISTORY OF CROHN'S DISEASE 55
Ó 2002 Blackwell Science Ltd, Aliment Pharmacol Ther 16, 51±60
cohorts.16±19, 21 The results are summarized in Table 6.
In all but one of the studies, the mean age at diagnosis
was between 33 and 39 years. The median age at
diagnosis (29.5 years) was available in only one
study.14
The so-called `bimodal' distribution of age at diagnosis
of Crohn's disease typically refers to a peak in incidence
in the second or third decades of life, followed by a
second (usually smaller) peak later in life, typically the
sixth or seventh decades. Such a distribution was noted
in four studies.18, 20, 22, 24 However, a `unimodal'
distribution, with a peak incidence in the second or
third decades, followed by a gradually diminishing
incidence thereafter, was also seen in four stud-
ies.14, 16, 19, 21 In a single study, the peak incidence
was seen after 50 years.17
Natural history of Crohn's disease
Natural history data may quantify the likelihood that a
patient with Crohn's disease will be in remission or will
be experiencing mild or severe disease activity at a given
point in time. These data suggest that most patients
with Crohn's disease are in remission during any given
year. A population-based study, performed in Olmsted
County, MN, described the lifetime clinical course of
Crohn's disease using disease states de®ned by medical
and surgical therapy, as outlined in Table 2, and a
Markov model analysis was used to calculate the time in
each disease state.8 In this study, a representative
patient spent 24% of the lifetime disease course in
medical remission, 27% with mild disease, 1% with
severe drug-responsive disease, 4% with severe drug-
dependent disease, 2% with severe drug-refractory
disease, 1% in surgery and 41% in post-surgical
remission (Table 7).
On the other hand, natural history data indicate that
only a small minority of Crohn's disease patients will
experience prolonged remission. An early study from
Olmsted County reported that 13% of patients had an
unremitting disease course, 73% had a chronic inter-
mittent disease course and 10% were `cured'.13 A
subsequent study from Olmsted County reported that,
over time, a decreasing proportion of patients are in a
medical remission state, and an increasing proportion of
patients are in a post-surgical remission state, while the
proportions of patients with mild disease, drug-respon-
sive disease, drug-dependent disease or drug-refractory
disease are relatively constant (Figure 1).8 However,






Nunes and Ahlquist17 1971, 1981 41 incidence 45*
Calkins et al.16 1977±79 180 incidence 35.6*
Pinchbeck et al.21 1981 1101 prevalence 33.9*
Hiatt and Kaufman18 1980±81 11 incidence 38.2*
Kurata et al.20 1987±88 169 prevalence 35.9
Loftus et al.14 1940±93 225 incidence 33.4
Bernstein et al.19 1989±94 997 incidence 37.7*
*Not explicitly stated, but estimated based on available data.
Table 6. Age of onset of Crohn's disease in
North America
Using median age Using mean age
Disease state Course (year) % Course (year) %
Remission 11.10 23.9 10.36 24.3
Mild 12.68 27.3 11.73 27.5
Severe, drug-responsive 0.41 0.9 0.38 0.9
Severe, drug-dependent 1.98 4.3 1.83 4.3
Severe, drug-refractory 0.82 1.8 0.76 1.8
Surgery 0.51 1.1 0.47 1.1
Post-surgery remission 18.88 40.7 17.11 40.1
Total 46.38 100 42.64 100
Table 7. Projected lifetime clinical course
for Crohn's disease (reprinted with
permission from Silverstein et al.8)
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whether the age at diagnosis, gender, disease location,
ethnicity or other possible prognostic factors will predict
patients that are likely to have a prolonged remission.
Further natural history data estimate the use of
medical therapy among patients with Crohn's disease.
A population-based study from Olmsted County repor-
ted that 43% of patients with Crohn's disease received
treatment with conventional corticosteroids at some
point in their disease history.9 During any given year,
approximately 10% of patients in Olmsted County were
treated with conventional corticosteroids or other
immune modi®er agents (Figure 1).8 During any
given year, approximately 30% of patients in Olmsted
County were treated with 5-aminosalicylate products
(Figure 1).8
Surgery also appears to be common in patients with
Crohn's disease, based on population-based studies. An
early study from Olmsted County reported that 41% of
patients with Crohn's disease underwent at least one
resection.7 A subsequent study from the same area
reported that 57% of patients underwent at least one
operative procedure.8
DISCUSSION
This systematic review of the incidence and preval-
ence of Crohn's disease in North America identi®ed
several important pieces of demographic information.
Firstly, the current prevalence of Crohn's disease in
North America is 144±198 cases per 100 000
persons. Secondly, the incidence rate of Crohn's
disease currently ranges between 3 and 14 new cases
per 100 000 person-years. Thirdly, there is a very
slight female predominance. Fourthly, the peak period
for the onset of Crohn's disease is in the second and
third decades of life.
Figure 2. Disease activity distribution in
the total patient group in each year from
diagnosis and 25 years ahead. (From year
14 to year 25, the mean values are given,
as no signi®cant change upwards or
downwards occurred.) Number of patients
(Pt) in parentheses (Reprinted with per-
mission from Munkholm et al.6).
Figure 1. Proportion of Crohn's disease
patients in each treatment state by year
since the diagnosis of Crohn's disease
(Reprinted with permission from Silverstein
et al.8).
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If the incidence rates of Crohn's disease identi®ed by
this systematic review are extrapolated to the North
American population as a whole, between 9000 and
44 000 new cases of Crohn's disease should be
diagnosed in North America annually. If recent preval-
ence data (144±198 cases per 100 000 persons) are
extrapolated to the entire North American population,
the current prevalence of Crohn's disease may be
between 400 000 and 600 000 cases. These estimates
have several limitations. Because they assume a uni-
form prevalence both geographically and across ethnic
groups, they may overestimate the prevalence. How-
ever, these ®gures may be an underestimate of the true
prevalence, as the only longitudinal prevalence data
available suggest that the prevalence of Crohn's disease
is increasing, and the data available are already
6±9 years old. Regardless of the exact number, these
data indicate that the burden of Crohn's disease in
North America is signi®cant.
The majority of patients with Crohn's disease are
diagnosed in the second or third decade of life. There
was a variation in the overall age distribution of cases,
however, with half of the studies suggesting a bimodal
distribution and half suggesting a unimodal distribu-
tion. The age distributions are likewise mixed in
European studies. Perhaps this may be explained by
misclassi®cation or by varying diagnostic criteria;
alternatively, the condition may be expressed heteroge-
neously under different environmental conditions.
Systematic reviews may be most helpful because they
identify new areas for research. The data in this
systematic review suggest that people in northern
latitudes and Caucasians are more likely to develop
Crohn's disease. The slight female predominance of
Crohn's disease was a fairly consistent ®nding, but its
cause and signi®cance remain unclear. In several of
these cohorts, a dramatic increase in incidence among
females in the third decade of life explained much of the
overall increase in incidence that occurred in the
1960s.14, 22 Such occurrences have led to speculation
about the role of female hormones in general, and oral
contraceptives and hormone replacement therapy in
particular, in the pathogenesis of Crohn's disease.
Although cigarette smoking, a well-described risk factor
for Crohn's disease, was not formally studied in these
cohorts, it also became more prevalent among women
in the 1960s, coincident with the rise in incidence and
prevalence. Future research focused on these issues may
better delineate the environmental, hormonal and
genetic factors which predispose patients to Crohn's
disease.
This systematic review also identi®ed several import-
ant pieces of information about the natural history of
Crohn's disease. At any given point in time following
the ®rst year of the disease, roughly 10% of Crohn's
disease patients have high activity, 25% have low
activity and 65% are in remission. However, a static
view of disease activity is misleading, as disease activity
often ¯uctuates. Approximately 13% of Crohn's disease
patients have chronically active disease, 73% have a
chronic intermittent course, while only 10% remain in
remission over many years. This pattern of disease
activity highlights the need for effective drug therapy,
both for the control of active disease and for the
maintenance of disease remission.
Approximately 43% of Crohn's disease patients
required conventional corticosteroids at some point in
their disease history, and roughly 10% required corti-
costeroids in any given year. About 30% of patients
required sulfasalazine or 5-aminosalicylate products in
any given year. Up to 57% of all patients required at
least one surgical resection.
The above natural history data were extracted from
several studies of a single population-based cohort in
North America,7±9 which may raise concern about the
generalizability of these data. However, the natural
history of Crohn's disease in Olmsted County is
surprisingly similar to that in Copenhagen County,
Denmark,3±6 which to our knowledge is the best-
characterized inception cohort of Crohn's disease in
either Europe or North America. A study of disease
activity performed in Copenhagen County reported that,
in the ®rst year after diagnosis, 80% of patients had
high disease activity, 15% had low activity and 5% were
in remission. After the ®rst year, 30% had high activity,
15% had low activity and 55% were in remission during
any given year (Figure 2).6 The same study reported the
clinical course over a continuous 5-year period (years
3±7); 25% of patients had active disease every year,
22% were in remission and 53% changed between years
with remission and years with relapse (Figure 3).6
Considering the ®rst 7 years, 20% of patients had active
disease every year, 13% had a relapse-free course and
67% ¯uctuated between years with relapse and years in
remission. In Copenhagen County, 56% of patients with
Crohn's disease received treatment with conventional
corticosteroids at some point in their disease history.5
During the ®rst 3 years following the diagnosis of
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Crohn's disease, 58% of patients did not receive
corticosteroid therapy, 19% received corticosteroids for
1 year and 22% received corticosteroids for two or
more years.6 During the ®rst 3 years following the
diagnosis of Crohn's disease, 20% of patients did not
receive therapy with 5-aminosalicylate products, 16%
received 5-aminosalicylate products for 1 year and 64%
received 5-aminosalicylate products for two or more
years.6 An early study from Copenhagen County
reported that 42% of patients with Crohn's disease
had one operation within 10 years of diagnosis and an
additional 13% had two or more operations within
10 years.3 A subsequent study from Copenhagen
County reported that the cumulative probability of
operation 15 years after the diagnosis of Crohn's
disease was 70%.4
The differences in the prevalence of use of medical and
surgical therapy in these two cohorts may re¯ect
differences in disease activity, but more likely re¯ect
differences in medical practice between the two locales.
The relatively high prevalence of conventional cortico-
steroid use highlights the burden of disease activity and
again points to the need for more effective and less toxic
drugs to control disease activity.
Overall, this review of the data has identi®ed several
areas that deserve attention in future research. The
information about natural history is based on fairly
limited data. Despite all that has been written about
Crohn's disease, we found only two population-based
cohorts in which medication usage, disease activity and
surgical history were described in detail.3±9 The natural
history data discussed above come from Olmsted
County, MN, USA and Copenhagen County, Denmark,
limiting the generalizability of these data. The develop-
ment of wider population-based networks of Crohn's
disease patients would be ideal to develop more
generalizable natural history data. The available data
also do not provide enough information to determine
whether age, gender, ethnicity, disease location or other
possible prognostic factors may help to predict which
patients are likely to be in remission for many years.
Finally, future prevalence and incidence data must
focus on environmental, hormonal and genetic factors
which may predispose patients to Crohn's disease. All of
these issues could be adequately addressed with the
development of a nationwide longitudinal database of
Crohn's disease patients.
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